摘要:

AbstractEighty patients with Stage III and IV head and neck cancer were treated with a four-drug regimen consisting of bleomycin, vincristine, methotrexate, and mitomycin-C (BOMM regimen). Of 69 patients evaluable for response, 7 complete and 40 partial responses were achieved, with an overall response rate of 68%. The median duration of response was 13 weeks (range 3-41 weeks). Anorexia, lassitude, febrile reactions, and myelosuppression were major side effects. The BOMM regimen produced a response rate significantly better than VCR, BLM, and MTx combination (VBM) which we previously reported with improved response duration. This study demonstrates that the BOMM regimen, which can be administered on an outpatient basis, achieved a response rate comparable to cisplatin-containing regimens. The BOMM regimen may be benejcial to patients with poor general condition and/or marginal renal dysfunction who are in high risk of toxicity-associated cisplatin-containing regimens.

ISSN:0735-7907    

DOI:10.3109/07357909109018946

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

摘要:

AbstractThe potential clinical usefulness of the fluorescent cytoprint assay (FCA) was assessed retrospectively in 73 cancer patients by correlating individual tumor chemosensitivity in vitro with responses to chemotherapy. The data show that the FCA has a sensitivity of 98%, specificity of 81%, and predictive accuracies of 85% and 97% for positive and negative clinical responses, respectively.

ISSN:0735-7907    

DOI:10.3109/07357909109018947

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

摘要:

AbstractUsing the newly developed hybrid spheroid system, we have been able to measure sensitivities to adriamycin in two sublines of LoVo cells (a human colon adenocarcinoma line). Hybrid spheroids are composed of coagglomerated LoVo cells, and nonproliferating HeLa“feeder”cells, mimicking a population of minitumors. Spheroids of uniform size, but containing different numbers of LoVo cells, were incubated with various concentrations of adriamycin and after washing, plated for colony formation. Binomial counting statistics were achieved by marking sugace-attached spheroids soon after plating, and scoring colonies one week later. From the fraction of noncolony formers, the average number of clonogens per spheroid (clonogenicity) was calculated using the zero term of the Poisson distribution. The effect of treatment with adriamycin was evaluated from the decrease in clonogenicity in parallel series of hybrid spheroids. Response to treatment was found to be independent of cellular clonogenicity in the control, untreated series. Dose-response curves were obtained for each of the two sublines after treatment for 1.5 h with various concentrations of adriamycin. The difference in the response to adriamycin between the two sublines amounted to a factor of 27 (deduced from D0ratios; these are the same as isosurvival dose ratios).

ISSN:0735-7907    

DOI:10.3109/07357909109018948

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

摘要:

AbstractRecent laboratory and clinical data suggest that some human neoplasms exhibit unusually high levels of cell-surface receptors for epidermal growth factor, and that this abnormality is associated with rapid cellular proliferation and poor prognosis. We propose that the existence of an abnormally high number of mitogen receptors is not merely correlated with rapid proliferation but is pathophysiologically responsible for such behavior. Cells with high levels of mitogen receptors may be rendered‘hypersensitive’to mitogenic stimuli, and hence may be stimulated to divide even when ambient mitogen concentrations are at a low‘background’level, insuficient to prompt the division of cells with a normal number of receptors. To investigate this hypothesis further, we have developed a mathematical model that describes proliferative behavior of cells as a finction of mitogen concentration and receptor number. The model enables us to simulate the proliferative behavior of cells with various receptor levels at various mitogen concentrations and predicts a growth advantage associated with excess mitogen receptors. Computer simulations based on the model are consistent with previously published experimental data. This work proviaks support for the view that overexpression of genes encoding normal growth factor receptors can contribute to the inappropriate prolifeation of neoplastic cells.

ISSN:0735-7907    

DOI:10.3109/07357909109018949

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

摘要:

AbstractPatients with malignancies or other prolonged illnesses such as acquired immune deficiency syndrome, require long-term vascular access. Unfortunately, currently available technologies which access the vascular system, such as intravenous catheters (external or implanted ports), have frequent complications including clotting and infection which limit their long-term usefulness. An important but forgotten method to access the central venous system is through the intraosseous route. This review summarizes past experience with the intraosseous route of access to the central venous system as well as describes a new device which might eventually make intraosseous access more convenient for the patient. It is anticipated this forgotten method of vascular access will be used more frequently in patients who have exhausted conventional venous access systems.

ISSN:0735-7907    

DOI:10.3109/07357909109018950

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

摘要:

AbstractInterleukin-2 (IL2) is the principal soluble factor responsible for the proliferation of activated T cells. In animal models and humans, administration of IL2 can induce regressions of established cancers. These antitumor effects may be partially mediated by cytotoxic effector cells activated by IL. 2, including lymphokine-activated killer (LAK) cells and cytotoxic T lymphocytes. IL2 has additional effects on other components of the cellular immune system, including B cells and macrophages, and induces secretion of other soluble mediators, including tumor necrosis factors (TNF) alpha and beta, and interferon-gamma. These effects may contribute to the antitumor activity of IL-2 as well as its dose-related toxicity. Multiple Phase I and II trials have been completed or are ongoing evaluating the clinical and biological effects of IL2 given by diverse routes and schedules, both alone and in combination with infusions of ex vivo IL2-activated autologour LAK cells. Other studies have begun to explore the potential for antitumor synergy when IL-2 is combined with the different interferons, TNF, monoclonal antibodies, and cytotoxic drugs. The biology, toxicity, and clinical activity documented in IL-2 clinical trials to date are reviewed, and prospects for future directions outlined.

ISSN:0735-7907    

DOI:10.3109/07357909109018951

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909109018952

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909109018953

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909109018954

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909109018955

出版商:Taylor&Francis    

年代:1991

数据来源: Taylor